Intellia Therapeutics Eyes 2026 Milestones for CRISPR-Based HAE Treatment — Intellia Therapeutics, Inc.

Event summary

Intellia expects topline Phase 3 data for lonvo-z in HAE by mid-2026, with BLA submission planned for H2 2026.
MAGNITUDE-2 Phase 3 trial for nex-z in ATTRv-PN enrollment completion expected in H2 2026.
FDA clinical hold on MAGNITUDE Phase 3 trial for nex-z in ATTR-CM remains unresolved.
Company ended 2025 with $605M in cash, sufficient to fund operations into H2 2027.

The big picture

Intellia's progress with lonvo-z represents a critical test case for CRISPR-based therapies in rare genetic disorders. The company's ability to navigate regulatory hurdles for nex-z will determine its pipeline diversity. With $605M in cash, Intellia has runway to pursue multiple clinical programs, but must deliver positive data to maintain investor confidence.

What we're watching

Regulatory Pathway: Whether Intellia can resolve the FDA clinical hold on the MAGNITUDE trial for nex-z in ATTR-CM.
Commercial Readiness: The pace at which Intellia can prepare for lonvo-z's potential U.S. launch in H1 2027.
Clinical Data Impact: How the Phase 3 data for lonvo-z will position it against existing HAE treatments.